GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Cyclically Adjusted Price-to-FCF

OASMY (Vivesto AB) Cyclically Adjusted Price-to-FCF : (As of Jun. 03, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vivesto AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Vivesto AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Cyclically Adjusted Price-to-FCF Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivesto AB Quarterly Data
Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivesto AB's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Vivesto AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Vivesto AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vivesto AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.005/132.8245*132.8245
=-0.005

Current CPI (Mar. 2025) = 132.8245.

Vivesto AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201504 -0.066 99.941 -0.088
201507 -0.071 100.027 -0.094
201510 -0.051 100.301 -0.068
201601 -0.107 99.931 -0.142
201604 -0.117 100.732 -0.154
201607 -0.085 101.080 -0.112
201610 -0.047 101.485 -0.062
201701 -0.085 101.326 -0.111
201704 -0.060 102.615 -0.078
201707 -0.074 103.301 -0.095
201710 -0.046 103.202 -0.059
201801 -0.052 102.925 -0.067
201804 -0.043 104.390 -0.055
201807 -0.028 105.420 -0.035
201810 -0.036 105.545 -0.045
201901 -0.038 104.855 -0.048
201904 -0.042 106.627 -0.052
201907 -0.043 107.166 -0.053
201910 -0.058 107.243 -0.072
202001 -0.044 106.215 -0.055
202004 0.089 106.240 0.111
202007 -0.058 107.731 -0.072
202010 -0.019 107.539 -0.023
202103 -0.053 108.360 -0.065
202106 -0.030 108.928 -0.037
202109 -0.020 110.338 -0.024
202112 -0.033 112.486 -0.039
202203 -0.015 114.825 -0.017
202206 -0.008 118.384 -0.009
202209 -0.012 122.296 -0.013
202212 -0.016 126.365 -0.017
202303 -0.013 127.042 -0.014
202306 -0.009 129.407 -0.009
202309 -0.010 130.224 -0.010
202312 -0.004 131.912 -0.004
202403 -0.009 132.205 -0.009
202406 -0.005 132.716 -0.005
202409 -0.006 132.304 -0.006
202412 -0.005 132.987 -0.005
202503 -0.005 132.825 -0.005

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vivesto AB  (OTCPK:OASMY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Vivesto AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Industry
Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.